Q32 Bio annual ebitda
2017
2018
2019
2020
2021
2022
2023
2024
2025
Q32 Bio EBITDA Growth & History (QTTB)
Q32 Bio's calculated EBITDA was $17.3M for fiscal 2025.
View full Q32 Bio company overviewQ32 Bio annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.3M | $82.9M | — |
| 2024 | 2024-12-31 | −$65.6M | −$17.9M | — |
| 2023 | 2023-12-31 | −$47.8M | $84.2M | — |
| 2022 | 2022-12-31 | −$132.0M | −$44.4M | — |
| 2021 | 2021-12-31 | −$87.6M | $34.7M | — |
| 2020 | 2020-12-31 | −$122.3M | −$18.7M | — |
| 2019 | 2019-12-31 | −$103.6M | −$45.0M | — |
| 2018 | 2018-12-31 | −$58.6M | −$29.7M | — |
| 2017 | 2017-12-31 | −$29.0M | — | — |
Q32 Bio quarterly ebitda
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$9.0M | $53,000 | — |
| Q1 2026 | 2026-03-31 | −$7.6M | $4.5M | — |
| Q4 2025 | 2025-12-31 | $46.0M | $60.3M | — |
| Q3 2025 | 2025-09-30 | −$7.5M | $11.2M | — |
| Q2 2025 | 2025-06-30 | −$9.1M | $8.7M | — |
| Q1 2025 | 2025-03-31 | −$12.1M | $2.6M | — |
| Q4 2024 | 2024-12-31 | −$14.4M | $11.4M | — |
| Q3 2024 | 2024-09-30 | −$18.7M | −$11.0M | — |
| Q2 2024 | 2024-06-30 | −$17.8M | −$10.7M | — |
| Q1 2024 | 2024-03-31 | −$14.7M | −$7.5M | — |
| Q4 2023 | 2023-12-31 | −$25.7M | $8.4M | — |
| Q3 2023 | 2023-09-30 | −$7.7M | $24.9M | — |
| Q2 2023 | 2023-06-30 | −$7.1M | $20.9M | — |
| Q1 2023 | 2023-03-31 | −$7.2M | $30.0M | — |
| Q4 2022 | 2022-12-31 | −$34.1M | −$2.6M | — |
| Q3 2022 | 2022-09-30 | −$32.6M | −$4.0M | — |
| Q2 2022 | 2022-06-30 | −$28.0M | $445,000 | — |
| Q1 2022 | 2022-03-31 | −$37.3M | −$38.2M | — |
| Q4 2021 | 2021-12-31 | −$31.6M | −$3.8M | — |
| Q3 2021 | 2021-09-30 | −$28.6M | −$2.3M | — |
| Q2 2021 | 2021-06-30 | −$28.5M | $5.2M | — |
| Q1 2021 | 2021-03-31 | $969,000 | $35.6M | — |
| Q4 2020 | 2020-12-31 | −$27.7M | −$3.9M | — |
| Q3 2020 | 2020-09-30 | −$26.3M | $3.3M | — |
| Q2 2020 | 2020-06-30 | −$33.7M | −$7.3M | — |
| Q1 2020 | 2020-03-31 | −$34.6M | −$10.7M | — |
| Q4 2019 | 2019-12-31 | −$23.8M | −$4.2M | — |
| Q3 2019 | 2019-09-30 | −$29.6M | −$14.3M | — |
| Q2 2019 | 2019-06-30 | −$26.4M | −$13.2M | — |
| Q1 2019 | 2019-03-31 | −$23.9M | −$13.4M | — |
| Q4 2018 | 2018-12-31 | −$19.6M | −$7.5M | — |
| Q3 2018 | 2018-09-30 | −$15.3M | −$8.9M | — |
| Q2 2018 | 2018-06-30 | −$13.2M | −$7.3M | — |
| Q1 2018 | 2018-03-31 | −$10.5M | −$5.9M | — |
| Q4 2017 | 2017-12-31 | −$12.1M | — | — |
| Q3 2017 | 2017-09-30 | −$6.5M | — | — |
| Q2 2017 | 2017-06-30 | −$5.9M | — | — |
| Q1 2017 | 2017-03-31 | −$4.6M | — | — |
Q32 Bio ebitda trends
Over the last five fiscal years, Q32 Bio's ebitda increased from −$122.3M to $17.3M, a change of $139.6M. The latest reported quarter, Q2 2026, shows −$9.0M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Q32 Bio source filings ↗Community posts
Q32 reports maintained hair-growth responses after treatment withdrawal
Q32 Bio ($QTTB) reported new off-treatment follow-up from the open-label Part B of its SIGNAL-AA study of bempikibart for severe alopecia areata. Among 12 patients who had shown hair growth by the end of 36 weeks of treatment and entered fo ...
